Physician profile
Hing B Luong
NPI 1588755722
$27,991.55
in general payments reported to CMS, 2019-2025
38 companies · $3,649 in 2025
The $3,649 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,991 · 2020: $2,084 · 2021: $4,089 · 2022: $4,824 · 2023: $4,448 · 2024: $4,907 · 2025: $3,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,898.56 |
| Education | $105.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,294.82 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $3,738.15 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Amgen INC. | $2,771.06 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $2,433.10 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,411.68 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $1,683.91 | 2021-2025 | |
| Lilly USA, LLC | $1,535.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,376.65 | 2019-2025 | Jardiance |
| Abbvie INC. | $1,052.92 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $904.63 | 2019-2023 | Xarelto |
| Corcept Therapeutics | $711.79 | 2023-2025 | Korlym |
| Mannkind Corporation | $599.97 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $527.06 | 2019-2025 | |
| Esperion Therapeutics, INC. | $500.97 | 2021-2025 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $419.33 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $345.64 | 2020-2025 | Vemlidy, Epclusa |
| Novartis Pharmaceuticals Corporation | $316.82 | 2019-2024 | |
| Becton, Dickinson and Company | $294.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $263.45 | 2019-2023 | Verquvo |
| Phathom Pharmaceuticals, INC. | $250.00 | 2024-2025 | Voquezna |
| Avanir Pharmaceuticals, INC. | $184.71 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $175.84 | 2024-2025 | Dupixent |
| Alkermes, INC. | $146.02 | 2021 | |
| Dexcom, INC. | $137.40 | 2022-2023 | Dexcom G7 Gss (161) |
| Abbott Laboratories | $136.63 | 2021-2023 | Freestyle Libre 3 |
| Organogenesis INC. | $125.03 | 2024 | Puraply Wound Matrix |
| Pfizer INC. | $125.00 | 2025 | |
| Angiodynamics, INC. | $111.11 | 2020 | |
| Biogen, INC. | $100.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $97.41 | 2024-2025 | Zoryve |
| Exact Sciences Corporation | $52.92 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Baxter Healthcare | $38.74 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $25.87 | 2022 | |
| Aimmune Therapeutics, INC. | $25.22 | 2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $23.93 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $22.94 | 2023 | Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $15.88 | 2022 | |
| Genentech USA, INC. | $14.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hing Luong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.